Epigenetic mechanisms underlying arsenic-associated lung carcinogenesis

Archives of Toxicology

Volumn 89, Issue 11, 2015, Pages 1959-1969

  van Breda, Simone G J ^a   Claessen, Sandra M H ^a   Lo, Ken ^b   van Herwijnen, Marcel ^a   Brauers, Karen J J ^a   Lisanti, Sofia ^c   Theunissen, Daniël H J ^a   Jennen, Danyel G J ^a   Gaj, Stan ^a   de Kok, Theo M C M ^a   Kleinjans, Jos C S ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b Roche Applied Science   (United States)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Arsenic; Data integration; Epigenomics; Genetic pathways; Lung cancer; Transcriptomics

Indexed keywords

ARSENIC; ARSENITE SODIUM; DNA; PROTEIN P53; RNA; ARSENOUS ACID DERIVATIVE; CARCINOGEN; SODIUM DERIVATIVE;

A549 CELL LINE; ARTICLE; CHEMICAL CARCINOGENESIS; CONTROLLED STUDY; DNA METHYLATION; EPIGENETICS; GENE EXPRESSION; GENE INTERACTION; GENOTOXICITY; HUMAN; HUMAN CELL; LUNG CANCER; LUNG CARCINOGENESIS; PRIORITY JOURNAL; TOXIC CONCENTRATION; TRANSCRIPTOMICS; ADENOCARCINOMA; CHEMICALLY INDUCED; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; LUNG TUMOR; PATHOLOGY; TIME FACTOR; TUMOR CELL LINE;

ADENOCARCINOMA; ARSENITES; CARCINOGENS; CELL LINE, TUMOR; DNA METHYLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; SODIUM COMPOUNDS; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84947577741     PISSN: 03405761     EISSN: 14320738     Source Type: Journal    
DOI: 10.1007/s00204-014-1351-2     Document Type: Article

References (51)

1. Azuma K et al (2012) NDRG1/Cap43/Drg-1 may predict tumor angiogenesis and poor outcome in patients with lung cancer. J Thorac Oncol 7(5):779–789
2. Baccarelli A et al (2009) Epigenetics and environmental chemicals. Curr Opin Pediatr 21(2):243–251
3. Bieging KT et al (2014) Unravelling mechanisms of p53-mediated tumour suppression. Nat Rev Cancer 14(5):359–370
4. Boellmann F et al (2010) Genome-wide analysis of DNA methylation and gene expression changes in the mouse lung following subchronic arsenate exposure. Toxicol Sci 117(2):404–417
5. Bustaffa E et al (2014) Genotoxic and epigenetic mechanisms in arsenic carcinogenicity. Arch toxicol
6. Cavigelli M et al (1996) The tumor promoter arsenite stimulates AP-1 activity by inhibiting a JNK phosphatase. EMBO J 15(22):6269–6279
7. Chang YS et al (2002) Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer. Clin Cancer Res 8(12):3669–3675
8. Chitale D et al (2009) An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors. Oncogene 28(31):2773–2783
9. Cline MS et al (2007) Integration of biological networks and gene expression data using Cytoscape. Nat Protoc 2(10):2366–2382
10. Cui X et al (2006) Chronic oral exposure to inorganic arsenate interferes with methylation status of p16INK4a and RASSF1A and induces lung cancer in A/J mice. Toxicol Sci 91(2):372–381
11. Dai M et al (2005) Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res 33(20):e175
12. Davis AP et al (2013) The comparative toxicogenomics database: update 2013. Nucleic Acids Res 41(D1):D1104–D1114
13. Eckhardt F et al (2006) DNA methylation profiling of human chromosomes 6, 20 and 22. Nat Genet 38(12):1378–1385
14. Gautier L et al (2004) Affy–analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 20(3):307–315
15. Gentleman RC et al (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5(10):R80
16. Guilleret I et al (2002) Hypermethylation of the human telomerase catalytic subunit (hTERT) gene correlates with telomerase activity. Int J Cancer 101(4):335–341
17. IARC (1987) Overall evaluations of carcinogenicity: an updating of IARC Monographs volumes 1 to 42. In: IARC Monogr Eval Carcinog Risks Hum Suppl, 1–440
18. Jennen DG et al (2010) Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci 115(1):66–79
19. Levin WJ et al (1995) Expression patterns of immediate early transcription factors in human non-small cell lung cancer. The lung cancer study group. Oncogene 11(7):1261–1269
20. Lisanti S et al (2012) Standardization and quality controls for the methylated DNA immunoprecipitation technique. Epigenetics 7(6):1–11
21. Liu J et al (2006) Further studies on aberrant gene expression associated with arsenic-induced malignant transformation in rat liver TRL1215 cells. Toxicol Appl Pharmacol 216(3):407–415
22. Mass MJ et al (1997) Arsenic alters cytosine methylation patterns of the promoter of the tumor suppressor gene p53 in human lung cells: a model for a mechanism of carcinogenesis. Mutat Res 386(3):263–277
23. Massion PP et al (2003) Significance of p63 amplification and overexpression in lung cancer development and prognosis. Cancer Res 63(21):7113–7121
24. Maunakea AK et al (2010) Conserved role of intragenic DNA methylation in regulating alternative promoters. Nature 466(7303):253–257
25. Melotte V et al (2010) The N-myc downstream regulated gene (NDRG) family: diverse functions, multiple applications. FASEB J 24(11):4153–4166
26. Meno SR et al (2009) Exposure to monomethylarsonous acid (MMA(III)) leads to altered selenoprotein synthesis in a primary human lung cell model. Toxicol Appl Pharmacol 239(2):130–136
27. Mo J et al (2009) Elevated human telomerase reverse transcriptase gene expression in blood cells associated with chronic arsenic exposure in Inner Mongolia China. Environ Health Perspect 117(3):354–360
28. Obe G et al (1992) DNA double-strand breaks induced by sparsely ionizing radiation and endonucleases as critical lesions for cell death, chromosomal aberrations, mutations and oncogenic transformation. Mutagenesis 7(1):3–12
29. Oliveros JC (2007) VENNY. An interactive tool for comparing lists with Venn Diagrams
30. Pogribny IP et al (1995) Differential sensitivity to loss of cytosine methyl groups within the hepatic p53 gene of folate/methyl deficient rats. Carcinogenesis 16(11):2863–2867
31. Putila JJ et al (2011) Association of arsenic exposure with lung cancer incidence rates in the United States. PLoS One 6(10):e25886
32. Reich M et al (2006) GenePattern 2.0. Nat Genet 38(5):500–501
33. Ren X et al (2011) An emerging role for epigenetic dysregulation in arsenic toxicity and carcinogenesis. Environ Health Perspect 119(1):11–19
34. Rubporn A et al (2009) Comparative proteomic analysis of lung cancer cell line and lung fibroblast cell line. Cancer Genomics Proteomics 6(4):229–237
35. Selenius M et al (2008) Treatment of lung cancer cells with cytotoxic levels of sodium selenite: effects on the thioredoxin system. Biochem Pharmacol 75(11):2092–2099
36. Shivapurkar N et al (2002a) Loss of expression of death-inducing signaling complex (DISC) components in lung cancer cell lines and the influence of MYC amplification. Oncogene 21(55):8510–8514
37. Shivapurkar N et al (2002b) Differential inactivation of caspase-8 in lung cancers. Cancer Biol Ther 1(1):65–69
38. Smeester L et al (2011) Epigenetic changes in individuals with arsenicosis. Chem Res Toxicol 24(2):165–167
39. Smyth GK (2005) Limma: linear models for microarray data. In: R. Gentleman VC, S. Dudoit, R. Irizarry, W. Huber (ed) Bioinformatics and Computational Biology Solutions using R and Bioconductor, Springer, New York, pp pages
40. Tapio S et al (2006) Arsenic in the aetiology of cancer. Mutat Res 612(3):215–246
41. Tchounwou PB et al (2003) Carcinogenic and systemic health effects associated with arsenic exposure–a critical review. Toxicol Pathol 31(6):575–588
42. Team RDC (2011) R: A language and environment for statistical computing. R Foundation for Statistical Computing. URL http://www.R-project.org/. Vienna, Austria
43. Wagner JR et al (2014) The relationship between DNA methylation, genetic and expression inter-individual variation in untransformed human fibroblasts. Genome Biol 15(2):R37
44. Weber M et al (2005) Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat Genet 37(8):853–862
45. Weber M et al (2007) Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat Genet 39(4):457–466
46. Woodson K et al (2001) Hypomethylation of p53 in peripheral blood DNA is associated with the development of lung cancer. Cancer Epidemiol Biomarkers Prev 10(1):69–74
47. Young MD et al (2011) ChIP-seq analysis reveals distinct H3K27me3 profiles that correlate with transcriptional activity. Nucleic Acids Res 39(17):7415–7427
48. Zhang AH et al (2011) Relationship between the methylation and mutation of p53 gene and endemic arsenism caused by coal-burning. Zhonghua yu fang yi xue za zhi Chinese journal of preventive medicine 45(5): 393–398
49. Zhou P et al (2005) Changes in gene expression profiles of multiple myeloma cells induced by arsenic trioxide (ATO): possible mechanisms to explain ATO resistance in vivo. Br J Haematol 128(5):636–644
50. Zhou X et al (2008) Arsenite alters global histone H3 methylation. Carcinogenesis 29(9):1831–1836
51. Zhu J et al (2003) Arsenic trioxide induces apoptosis in leukemia/lymphoma cell lines via the CD95/CD95L system. Oncol Rep 10(3):705–709